Latest Breaking News On - Zevra therapeutics inc - Page 16 : comparemela.com

ACER THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acer Therapeutics Inc - ACER -October 10, 2023 at 10:29 am EDT

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC are investigating the proposed sale of Acer Therapeutics Inc. to Zevra Therapeutics, Inc..

United statesCharlesc foti jrLewiss kahnAcer therapeutics incZevra therapeutics incKahn swick fotiFormer attorney generalLouisiana charlesKahn swickAcer therapeuticsZevra therapeuticsContingent value rightsPartner lewisFormer louisiana attorney general

Zevra Therapeutics Names Neil McFarlane President, CEO

(RTTNews) - Zevra Therapeutics, Inc. (ZVRA), a rare disease therapeutics company, announced Tuesday the appointment of Neil McFarlane as President.

Joseph saluriChristal mickleBoard of directors adamas pharmaceuticals incSupernus pharmaceuticals incTravere therapeutics incGenzyme corpUcb incZevra therapeutics incDevelopment officerCollegium pharmaceutical incRetrophin incMore such health newsSangstat medical corpNeil mcfarlaneChief executive officerChief development

Zevra Therapeutics Appoints Neil F McFarlane as President, Chief Executive Officer and Director

Zevra Therapeutics Appoints Neil F McFarlane as President, Chief Executive Officer and Director
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesChristalmm mickleNichol ochsnerJoe saluriJanine bogrisTamaraa seymour favoritoNeilf mcfarlaneJosephb saluriChristal mickleRetrophin incUniversity of floridaTravere therapeutics incCompensation committee of zevra board directorsDevelopment officerUnited states armySangstat medical corporation

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Zevra Therapeutics Announces Interim Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNichol ochsnerJanine bogrisRene braeckmanUs drug enforcement agencyClinical developmentExchange commissionZevra therapeutics incDrug administrationSenior vice presidentEpworth sleepiness scalePatient global impressionClinical global impressionIdiopathic hypersomnia severity scaleIdiopathic hypersomniaOrphan drug designation

Zevra Therapeutics to Participate in the Cantor Global

CELEBRATION, Fla., Sept. 20, 2023 (GLOBE NEWSWIRE) Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics.

Janine bogrisNichol ochsnerExchange commissionZevra therapeutics incCantor global healthcare conferenceInvestor relationsZevra therapeuticsConcerning forward looking statementsPrivate securities litigation reform actAnnual reportQuarterly reportNasdaq zvraZevra therapeutics